<DOC>
	<DOCNO>NCT02213133</DOCNO>
	<brief_summary>Open-label , multi-center , single-arm , Phase 2 study oral selinexor patient SCC head neck ( HN-SCC ; Cohort 1 ) , lung ( L-SCC ; Cohort 2 ) , esophagus ( E-SCC ; Cohort 3 ) relapse metastasis follow chemotherapy .</brief_summary>
	<brief_title>Selinexor Treatment Advanced Relapsed/Refractory Squamous Cell Carcinomas</brief_title>
	<detailed_description>This multicenter , open-label , single-arm Phase 2 study SINE selinexor give orally patient diagnose advanced SCC head neck , lung , esophagus experience relapse and/or metastasis follow multiple prior chemotherapy treatment ( &lt; 2 line therapy ) . Patients receive fixed dos selinexor tablet twice weekly 28-day cycle . Patients may continue one cycle next without interruption along criterion meet reason discontinuation occur .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>18 year age old confirm SCC head neck , lung , esophagus 1 2 prior therapy measurable disease screen document progression within past 6 week patient require total parenteral nutrition unstable cardiovascular function substantially impair gastrointestinal function Symptomatic brain metastases another malignancy within 3 year except adequately treat situ carcinoma type , basal nonmelanomatous skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Squamous</keyword>
	<keyword>SCC</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>KPT-330</keyword>
	<keyword>SINE</keyword>
	<keyword>Selinexor</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Karyopharm Therapeutics</keyword>
	<keyword>Lung</keyword>
	<keyword>Head</keyword>
	<keyword>Neck</keyword>
	<keyword>Esophageal</keyword>
</DOC>